The epidemiologic, health-related quality of life, and economic burden of gastrointestinal stromal tumours

Summary Background and objectives: Gastrointestinal stromal tumours (GIST) are uncommon tumours believed to arise from interstitial cells of Cajal or their precursors in the gastrointestinal (GI) tract, accounting for a small percentage of GI neoplasms and sarcomas. Given the recent recognition of GIST as a distinct cancer, as well as new treatment options available today, a review of the epidemiologic, health‐related quality of life (HRQL), and economic burden of GIST is timely from a payer, provider and patient perspective and may provide guidance for treatment decision making and reimbursement. Methods: A systematic literature review of PubMed and five scientific meeting databases, was conducted to identify published studies and s describing the epidemiologic, HRQL and economic impact of GIST. Publications deemed worthy of further review, based on the information available in the , were retrieved in full text. Results and discussion: Thirty‐four publications met the review criteria: 29 provided data on GIST epidemiology, one provided cost data, three reported HRQL outcomes, and one reported cost and HRQL outcomes. The annual incidence of GIST (cases per million) ranged from 6·8 in the USA to 14·5 in Sweden, with an estimated 5‐year survival rate of 45–64%. On the Functional Illness of Chronic Therapy‐fatigue instrument, GIST patients scored 40·0 compared with 37·6 in anaemic cancer patients (0 = worst; 52 = least fatigue). Total costs over 10 years for managing GIST patients with molecularly targeted treatment was estimated at £47 521–£56 146 per patient compared with £4047–£4230 per patient with best supportive care. Conclusions: The incidence of GIST appears to be similar by country; the lower estimate in one country could be explained by differences in method of case ascertainment. Data suggest that the HRQL burden of GIST is similar to that with other cancers although this requires further exploration. The value of new therapies in GIST needs to consider not only cost but also anticipated benefits and the unmet medical need in this condition.